Roskos L - Search Results

1

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.

Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Johnston E, et al. Among authors: roskos l. J Clin Oncol. 2000 Jul;18(13):2522-8. doi: 10.1200/JCO.2000.18.13.2522. J Clin Oncol. 2000. PMID: 10893282 Clinical Trial.

2

Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Roskos LK, et al. J Clin Pharmacol. 2006 Jul;46(7):747-57. doi: 10.1177/0091270006288731. J Clin Pharmacol. 2006. PMID: 16809800 Clinical Trial.

3

Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques.

Farese AM, Yang BB, Roskos L, Stead RB, MacVittie TJ. Farese AM, et al. Among authors: roskos l. Bone Marrow Transplant. 2003 Aug;32(4):399-404. doi: 10.1038/sj.bmt.1704156. Bone Marrow Transplant. 2003. PMID: 12900776

4

Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK. Wang B, et al. Among authors: roskos lk. J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42. doi: 10.1023/a:1011534529622. J Pharmacokinet Pharmacodyn. 2001. PMID: 11677930

5

Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.

Yang BB, Lum PK, Hayashi MM, Roskos LK. Yang BB, et al. J Pharm Sci. 2004 May;93(5):1367-73. doi: 10.1002/jps.20024. J Pharm Sci. 2004. PMID: 15067712

6

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE. Deeg HJ, et al. Among authors: roskos lk. Blood. 2001 Oct 1;98(7):2052-8. doi: 10.1182/blood.v98.7.2052. Blood. 2001. PMID: 11567989 Free article. Clinical Trial.

7

Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab.

Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, Pérez Ruixo JJ. Yang BB, et al. Among authors: roskos l. Clin Pharmacokinet. 2010 Nov;49(11):729-40. doi: 10.2165/11535970-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923247 Review.

8

Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases.

Tabrizi M, Wang B, Lu H, Huang S, Bell G, Schwab G, Roskos L. Tabrizi M, et al. Among authors: roskos l. Inflamm Allergy Drug Targets. 2010 Sep;9(4):229-37. doi: 10.2174/187152810793358796. Inflamm Allergy Drug Targets. 2010. PMID: 20860546 Clinical Trial.

9

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.

Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Foon KA, et al. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. doi: 10.1016/j.ijrobp.2003.09.098. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967460 Review.

10

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.

Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. Jakobovits A, et al. Among authors: roskos l. Nat Biotechnol. 2007 Oct;25(10):1134-43. doi: 10.1038/nbt1337. Nat Biotechnol. 2007. PMID: 17921999

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters